ES2189079T3 - Efectos inmunosupresores de derivados de xantina 8-sustituidos. - Google Patents
Efectos inmunosupresores de derivados de xantina 8-sustituidos.Info
- Publication number
- ES2189079T3 ES2189079T3 ES98201323T ES98201323T ES2189079T3 ES 2189079 T3 ES2189079 T3 ES 2189079T3 ES 98201323 T ES98201323 T ES 98201323T ES 98201323 T ES98201323 T ES 98201323T ES 2189079 T3 ES2189079 T3 ES 2189079T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- carbon atoms
- unsubstituted
- phenyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001506 immunosuppresive effect Effects 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- 125000001931 aliphatic group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- -1 N-substituted sulfonamide Chemical class 0.000 abstract 1
- ABDMQSFNJPYOLA-UHFFFAOYSA-N NS(=O)(=O)[N+]([O-])=O Chemical class NS(=O)(=O)[N+]([O-])=O ABDMQSFNJPYOLA-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001033 ether group Chemical group 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA INVENCION SE REFIERE A UN NUEVO USO DE DERIVADOS DE LA XANTINA 8-SUSTITUIDA PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES. LA INVENCION SE REFIERE EN PARTICULAR A LA UTILIZACION DE UN DERIVADO DE LA XANTINA DE LA FORMULA GENERAL (I) EN DONDE: R 1 , R 2 Y R 3 SON INDEPENDIENTEMENTE HIDROGENO, CADENAS ALIFATICAS SATURADAS O INSATURADAS QUE PUEDEN SER RECTAS O RAMIFICADAS QUE TIENEN ENTRE 1 Y 6 ATOMOS DE CARBONO; X E Y SON INDEPENDIENTEMENTE OXIGENO O AZUFRE; Z 1 SE SELECCIONA ENTRE EL GRUPO QUE CONSTA DE TIENILO; FURANILO; CICLOPENTILO, FENILO O UN FENILO SUSTITUIDO POR 2 O INSUSTITUIDO; EN DONDE Z 2 SE SELECCIONA ENTRE EL GRUPO QUE CONSTA DE FENILO; ACIDO SULFONICO; SULFONAMIDA INSUSTITUIDA O N-SUSTITUIDA CON SUSTITUYENTES TALES COMO ALQUILO, AMINOALQUILO EN DONDE EL GRUPO DE AMINO PUEDE ESTAR EL MISMO SUSTITUIDO CON GRUPOS DE ALQUILO INFERIOR QUE SOPORTAN ENTRE 1 Y 4 ATOMOS DE CARBONO; NITRO; UN GRUPO DE AMINO SUSTITUIDO CON HALOGENO O INSUSTITUIDO; UNA CADENA ALIFATICA CON ENTRE 1 Y 3 ATOMOS DE CARBONO; UNA CADENA ALIFATICA HOLOGENADA CON ENTRE 1 Y 3 ATOMOS DE CARBONO; UNA CADENA ALIFATICA QUE CONTIENE FUNCIONES DE ETER, ACIDOS, ESTERES, AMIDOS, AMINOS SUSTITUIDOS O INSUSTITUIDOS QUE TIENEN ENTRE 1 Y 3 ATOMOS DE CARBONO, NITRO, SULFONAMIDOS O UNA COMBINACION DE ESTOS GRUPOS FUNCIONALES CON UN LONGITUD MAXIMA DE LA CADENA DE 12 ATOMOS. TAMBIEN SE PRESENTAN LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS DERIVADOS QUE SE UTILIZAN PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98201323A EP0956855B1 (en) | 1998-04-24 | 1998-04-24 | Immunosuppressive effects of 8 substituted xanthine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2189079T3 true ES2189079T3 (es) | 2003-07-01 |
Family
ID=8233642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98201323T Expired - Lifetime ES2189079T3 (es) | 1998-04-24 | 1998-04-24 | Efectos inmunosupresores de derivados de xantina 8-sustituidos. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0956855B1 (es) |
| AT (1) | ATE234099T1 (es) |
| DE (1) | DE69812070T2 (es) |
| DK (1) | DK0956855T3 (es) |
| ES (1) | ES2189079T3 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002533464A (ja) * | 1998-12-28 | 2002-10-08 | カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント | プテリジン誘導体の免疫抑制作用 |
| US7276506B2 (en) | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| AU2002359365B2 (en) | 2001-11-09 | 2008-07-10 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7317017B2 (en) | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| BR0302965A (pt) * | 2002-02-01 | 2005-02-09 | King Pharmaceuticals Res & Dev | Composto e método de tratar doenças mediadas por receptores de adenosina a2b |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| ATE403656T1 (de) * | 2003-05-06 | 2008-08-15 | Cv Therapeutics Inc | Xanthinderivate als a2b- adenosinrezeptorantagonisten |
| AU2011202523B2 (en) * | 2003-11-21 | 2013-05-30 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
| US20070078121A1 (en) | 2004-12-23 | 2007-04-05 | Flynn Daniel L | Enzyme modulators and treatments |
| US10144736B2 (en) | 2006-07-20 | 2018-12-04 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| EA200970700A1 (ru) | 2007-04-20 | 2010-02-26 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний |
| US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
| MX2011004535A (es) | 2008-10-29 | 2011-11-18 | Deciphera Pharmaceuticals Llc | Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas. |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| AU2015330490B2 (en) | 2014-10-09 | 2018-08-09 | Guangdong Raynovent Biotech Co., Ltd. | Hydroxyl purine compounds and applications thereof |
| CN105566324B (zh) * | 2014-10-09 | 2020-04-03 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
| CN107108615B (zh) | 2015-03-04 | 2020-11-20 | 吉利德科学公司 | Toll样受体调节性4,6-二氨基-吡啶并[3,2-D]嘧啶化合物 |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| EP3507276B1 (en) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CN110041330B (zh) * | 2018-01-16 | 2020-08-11 | 新发药业有限公司 | 一种伊曲茶碱的环保制备方法 |
| CN111818915B (zh) | 2018-01-31 | 2024-05-24 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| KR20220045189A (ko) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양을 치료하는 방법 |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| CN110922363A (zh) * | 2019-12-28 | 2020-03-27 | 新华制药（寿光）有限公司 | 一种紫脲酸连续化生产工艺 |
| JP2023509628A (ja) | 2019-12-30 | 2023-03-09 | デシフェラ・ファーマシューティカルズ，エルエルシー | １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物 |
| EP4327827A3 (en) | 2019-12-30 | 2024-05-29 | Deciphera Pharmaceuticals, LLC | Amorphous kinase inhibitor formulations and methods of use thereof |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL100195A0 (en) * | 1990-11-30 | 1992-08-18 | Hoechst Roussel Pharma | Use of xanthines for the preparation of a medicament having immuno suppressing activity |
| JPH11505241A (ja) * | 1995-05-19 | 1999-05-18 | カイロサイエンス・リミテッド | キサンチン類およびこれらの治療的使用 |
-
1998
- 1998-04-24 AT AT98201323T patent/ATE234099T1/de not_active IP Right Cessation
- 1998-04-24 DE DE69812070T patent/DE69812070T2/de not_active Expired - Fee Related
- 1998-04-24 ES ES98201323T patent/ES2189079T3/es not_active Expired - Lifetime
- 1998-04-24 EP EP98201323A patent/EP0956855B1/en not_active Expired - Lifetime
- 1998-04-24 DK DK98201323T patent/DK0956855T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP0956855A1 (en) | 1999-11-17 |
| DE69812070D1 (de) | 2003-04-17 |
| DE69812070T2 (de) | 2003-12-11 |
| ATE234099T1 (de) | 2003-03-15 |
| EP0956855B1 (en) | 2003-03-12 |
| DK0956855T3 (da) | 2003-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2189079T3 (es) | Efectos inmunosupresores de derivados de xantina 8-sustituidos. | |
| ES2082805T3 (es) | Derivados de tiazol, procedimientos para su produccion y composiciones farmaceuticas que comprenden los mismos. | |
| NO933452L (no) | Et terapeutisk middel for Parkinson's sykdom | |
| ES2065895T3 (es) | 2-aminobenzotiazoles sustituidos y derivados de los mismos utiles como agentes cerebrovasculares. | |
| ATE282614T1 (de) | Phenylharnstoff und phenylthioharnstoffderivate | |
| ATE52498T1 (de) | Amidderivate. | |
| ATE121939T1 (de) | Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion. | |
| IL129824A (en) | Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants | |
| BR1100636A (pt) | Agente terapêutico para o mal de parkinson, e, derivado da xantina | |
| ATE83773T1 (de) | 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a. | |
| FR2598709B1 (fr) | Derives de l'acide quinoleinecarboxylique | |
| DK0790987T3 (da) | Aminotetrazol-derivater, der er anvendelige som nitrogenoxidsynthaseinhibitorer | |
| ES2110977T3 (es) | Espiro-isoquinolein-pirrolidinas y analogos de las mismas, utiles como inhibidores de la aldosa-reductasa. | |
| BRPI0408675A (pt) | derivados de talidomida solúveis em água | |
| ES2131549T3 (es) | Derivados macrolidas de 16 eslabones y su procedimiento de preparacion. | |
| DK384485D0 (da) | 1,6-naphthyridinderivater med kardilaterende virkning | |
| ES2061785T3 (es) | Benzopiranos 2,2-disustituidos de utilidad como antagonistas de leucotrieno-d4. | |
| EP0726269A4 (en) | QUINOLINE CARBONIC ACID DERIVATIVE AND ITS SALTS | |
| ATE222583T1 (de) | Derivate substituierter amidinonaphthylester | |
| KR910006292A (ko) | 방향족 산의 n-아자비시클로 [3.3.0] 옥탄 아미드 | |
| KR910000150A (ko) | 대사성 골 질환 치료제 | |
| DE69532963D1 (de) | Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen | |
| TH31604A (th) | อนุพันธ์ของไอโซอินโดล วิธีการเตรียมและการใช้อนุพันธ์ของไอโซอินโดลให้เป็นประโยชน์ในการบำบัดรักษาโรค |